Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Zacks Investment Research on MSN22h
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down AftermarketBio-Rad Laboratories, Inc. BIO posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.90, which missed the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback